Oxime Compounds for Acetylcholinesterase Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for organophosphate poisoning, such as those caused by nerve agents like VX and sarin, rely on outdated methods involving anti-cholinergic drugs and oximes, and there is a need for more effective and innovative therapeutics to manage the acute cholinergic crisis and nerve damage.
Innovation Solution
Development of novel organic compounds, specifically oximes of Formula (I), (III), (V), (VII), and (IX), which reactivate acetylcholinesterase enzyme to reduce acetylcholine accumulation and alleviate symptoms of organophosphate poisoning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard treatment protocols using anti-cholinergic drugs and oximes are used, then the acute cholinergic crisis can be managed, but the treatment effectiveness is limited and brain damage occurs
Solution Approach 1:
The patent modifies the chemical structure of oxime compounds by changing parameters such as introducing specific substituents (nitro, cyano, halo groups) and modifying the R1-R6 positions to enhance binding affinity with AChE and improve reactivation efficiency, thereby treating the organophosphate poisoning more effectively while reducing brain damage
Solution Approach 2:
The invention creates composite molecular structures by combining multiple functional groups and substituents in the oxime compounds (Formulas I, III, V, VII, IX) to achieve both high binding affinity with AChE and effective reactivation, resolving the contradiction between treatment effectiveness and prevention of nerve damage
2Reliability
If existing oxime compounds are used to reactivate AChE, then acetylcholine accumulation can be reduced, but the binding affinity and reactivation potential are insufficient
Solution Approach 1:
The patent systematically modifies molecular parameters of oxime compounds by introducing specific substituents (nitro at R1, cyano at R1, halo at R2) and adjusting structural parameters (R3-R6 groups, ring sizes 4-6 members) to optimize binding affinity with AChE and enhance reactivation potential
Solution Approach 2:
The invention divides the molecular structure into distinct functional segments (oxime core, substituent groups at specific positions, ring structures) to independently optimize each component's contribution to binding affinity and reactivation, allowing precise control over the interaction with AChE
3Speed
If fast-acting treatments are developed, then the acute cholinergic crisis can be addressed quickly, but the treatment must be highly specific and personalized
Solution Approach 1:
The patent develops a series of oxime compounds with different structural variants (Formulas I, III, V, VII, IX) that can universally address various organophosphate nerve agents while maintaining fast action, reducing the need for highly personalized treatment protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate high binding affinity and reactivation potential for AChE, providing a fast, cost-effective, and personalized treatment approach for organophosphate exposure, supporting improved patient management and clinical response.
Implementation Method 1
oximes work as an antidote for organophosphate poisoning by reactivating the inhibited acetylcholinesterase
Implementation Method 2
The oxime attaches itself to both the acetylcholinesterase and the organophosphate molecule, helping to break the bond between them
Implementation Method 3
acetylcholinesterase, thereby reducing the accumulation of acetylcholine and restoring normal nervous system function
Data Source
AI summary
Described herein are compounds that reactivate acetylcholinesterase and associated methods of treating organophosphate poisoning.